TRAVERSA SERGIO (Chief Executive Officer) purchased 57.4% of their position (140K shares) of RELMADA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $395.1K — a major conviction buy. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 9/11/2024ACC: 0001213900-24-077795
DirectorOfficer· Chief Executive Officer
Since Dec 2018
+140K
Net shares
Net buyer
$395.1K
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
140K acquired
Non-Derivative Transactions3
Common Stock
Direct
Shares
+55.58K
Price / share
$2.71
Trade value
$150.62K
% of position
22.8%
9/9/2024
244.02K→299.60K
Common Stock
Direct
Shares
+33.01K
Price / share
$2.75
Trade value
$90.79K
% of position
11.0%
9/10/2024
299.60K→332.62K
Common Stock
Direct
Shares
+51.41K
Price / share
$2.99
Trade value
$153.71K
% of position
15.5%
9/11/2024
332.62K→384.02K
Total
Net shares
+140K
Net value
$395.11K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/9/2024 | P · Purchase | +55.58K | $2.71 | $150.62K | 22.8% | 244.02K | 299.60K |
| Common Stock Direct | 9/10/2024 | P · Purchase | +33.01K | $2.75 | $90.79K | 11.0% | 299.60K | 332.62K |
| Common Stock Direct | 9/11/2024 | P · Purchase | +51.41K | $2.99 | $153.71K | 15.5% | 332.62K | 384.02K |
| Total | +140K | $395.11K | ||||||
Derivative Transactions0
No derivative transactions reported